Budgetary impact of using BPaL for treating extensively drug-resistant tuberculosis

• Christiaan Mulder,
• Susan van den Hof,
• Shelly Malhotra,
• Sarah Cook-Scalise,
• Sandeep Juneja,
• Stephan Rupert,
• Ery Setiawan,
• Elmira Mambetova,
• Patience Edo,
• Jhon Sugiharto,
• Sani Useni,
• Imran Pambudi,
• Abdullaat Kadyrov,
• Adebola Lawanson,
• Agnes Gebhard,
• Hojoon Sohn

Affiliations

Christiaan Mulder

Technical Division, KNCV Tuberculosis Foundation, The Hague, The Netherlands

Susan van den Hof

Technical Division, KNCV Tuberculosis Foundation, The Hague, The Netherlands

Shelly Malhotra

Market Access, Global Alliance for TB Drug Development, New York, New York, USA

Sarah Cook-Scalise

Market Access, Global Alliance for TB Drug Development, New York, New York, USA

Sandeep Juneja

Market Access, Global Alliance for TB Drug Development, New York, New York, USA

Stephan Rupert

Amsterdam Institute for Global Health and Development, Amsterdam University Medical Centres, Amsterdam, The Netherlands

Ery Setiawan

Universitas Indonesia, Depok, Indonesia

Elmira Mambetova

KNCV Tuberculosis Foundation, Bishkek, Kyrgyzstan

Patience Edo

KNCV Tuberculosis Foundation, Abuja, Nigeria

Jhon Sugiharto

Yayasan KNCV Indonesia, Jakarta, Indonesia

Sani Useni

KNCV Tuberculosis Foundation, Abuja, Nigeria

Imran Pambudi

National TB Program, Ministry of Health of the Republic of Indonesia, Jakarta, Indonesia

Abdullaat Kadyrov

National Center of Phtiziatry, National TB Program, Bishkek, Kyrgyzstan

Adebola Lawanson

National Tuberculosis and Leprosy Control Programme, Federal Ministry of Health, Abuja, Nigeria

Agnes Gebhard

Technical Division, KNCV Tuberculosis Foundation, The Hague, The Netherlands

Hojoon Sohn

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA